Skip to main content

Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience



Commonly known as Batten disease, the neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of rare pediatric lysosomal storage disorders characterized by the intracellular accumulation of autofluorescent material (known as lipofuscin), progressive neurodegeneration, and neurological symptoms. In 2002, a disease-causing NCL mutation in the CLN6 gene was identified (c.214G > T) in the Costa Rican population, but the frequency of this mutation among local Batten disease patients remains incompletely characterized, as do clinical and demographic attributes for this rare patient population.


To describe the main sociodemographic and clinical characteristics of patients with a clinical diagnosis for Batten Disease treated at the National Children's Hospital in Costa Rica and to characterize via molecular testing their causative mutations.


DNA extracted from buccal swabs was used for CLN6 gene sequencing. Participants’ sociodemographic and clinical characteristics were also obtained from their medical records.


Nine patients with a clinical diagnosis of Batten disease were identified. Genetic sequencing determined the presence of the previously described Costa Rican homozygous mutation in 8 of 9 cases. One patient did not have mutations in the CLN6 gene. In all cases where the Costa Rican CLN6 mutation was present, it was accompanied by a substitution in intron 2. Patients were born in 4 of the 7 Costa Rican provinces, with an average onset of symptoms close to 4 years of age. No parental consanguinity was present in pedigrees. Initial clinical manifestations varied between patients but generally included: gait disturbances, language problems, visual impairment, seizures and psychomotor regression. Cortical and cerebellar atrophy was a constant finding when neuroimaging was performed. Seizure medication was a common element of treatment regimens.


This investigation supports that the previously characterized c.214G > T mutation is the most common causative NCL mutation in the Costa Rican population. This mutation is geographically widespread among Costa Rican NCL patients and yields a clinical presentation similar to that observed for CLN6 NCL patients in other geographies.


Neuronal ceroid lipofuscinoses (NCLs) constitute a group of genetic neurodegenerative diseases associated with motor and cognitive regression; progressive cortical, thalamic, and cerebellar atrophy; retinopathy; epilepsy; and a shortened lifespan [1, 2]. NCLs causative mutations have been mapped to at least 13 different genes, which encode a diverse set of lysosomal enzymes, cytosolic chaperones, and transmembrane proteins with roles in secretory and endolysosomal trafficking [3]. More than 70 mutations have been reported in the CLN6 gene, which are responsible for variant late infantile or adult-onset forms (i.e. Kufs Disease Type A) of NCL [4,5,6]. The CLN6 gene is located on 15q23 and encodes a 311 amino acid transmembrane endoplasmic reticulum protein that functions in the ER to Golgi transfer of lysosomal enzymes [7]. Downstream cellular pathologies ranging from synaptic alterations, glial activation, and autophagy have also hinted at additional cellular roles or, perhaps, specialized roles in neurons and glia [2, 6, 8,9,10,11,12].

The initial clinical manifestations of CLN6 disease generally begin between the ages of 2 and 4 years [13] and are characterized by motor regression, visual loss, the presence of rapid and involuntary muscle movements, and multiple seizures types [14, 15]. In advanced stages, patients commonly develop ataxia, further cognitive and motor deterioration, and finally spastic quadriparesia [16, 17]. Imaging-based studies commonly find cortical and/or subcortical grey matter atrophy [15, 17,18,19] and, like most other forms of NCL, there are no approved disease-modifying treatments. Clinical treatment is focused on symptom management and includes the management of seizures, sleep alterations, extrapyramidal symptoms, behavioral disturbances, anxiety and psychosis [14]. Slight variations in the clinical course of CLN6 disease have been linked to the causative mutations and the country of origin [20].

Mutations in the CLN6 gene are observed mainly in patients of Portuguese, Indian, Pakistani or Czech descent, but have also been documented in countries such as Costa Rica, Sudan, Turkey and Japan [16, 21,22,23]. By the end of the 1990s, studies aimed at identifying and analyzing the most common genetic variant in late infantile NCL began in the Costa Rican population [24,25,26]. From these studies, the causative alteration known as the Costa Rican CLN6 gene mutation was defined [27]. This genetic modification, described in 2002, corresponds to a nonsense change in exon 3 (c.214G> T; p.E72X) introducing a stop codon at amino acid position 72; which results in a premature termination and generates an incomplete and non-functional protein product that is degraded at the level of the endoplasmic reticulum [6, 22]. Other possible disease-related mutations in the CLN6 gene (specifically in exons 4 [c.368G> A] and 7 [c.722T> C]) have also been reported [28]. Currently in Costa Rica, a NCL diagnosis is made by a clinical evaluation of the symptoms and signs recalled during medical history and present during physical examination by a pediatric neurologist.

Here, we aimed to determine the frequency of the c.214G>T CLN6 gene mutation and any other mutations among Costa Rican NCL patients and to describe the main sociodemographic and clinical characteristics in patients diagnosed with NCL in the National Children's Hospital (HNN), the only pediatric hospital in Costa Rica, and part of the social security system (CCSS).


After obtaining approval from the Institution’s Scientific Ethics Committee (CEC-CENTRAL-CCSS) and authorization from the Director of Costa Rica´s National Children´s Hospital (HNN), the parents of all patients with a clinical diagnosis of Batten disease currently treated at the HNN Neurology Department were contacted, the study was explained and the investigators invited the parents so their child could participate. Subsequently, an appointment was scheduled in the HNN and, after explaining the study and obtaining informed consent (informed assent was not possible), the investigator collected a buccal swab for each participant. The samples were disassociated from any personal identification and transported in compliance with international regulations to the appointed laboratory. The genetic analysis of the samples was performed by Sanford Research (Sioux Falls, SD; USA) in two independent laboratories where DNA was extracted and next generation sequencing (NGS) for the CLN6 gene was performed for each study subject. Once the genetic results were obtained, the study participant´s parents received the genetic testing results with an explanation as part of their usual clinical visit.

The main sociodemographic and clinical characteristics from the study subjects were examined with a descriptive analysis based on existing medical records. These included: age, sex, place of birth and residence, age of initial symptom onset, age of clinical diagnosis, relevant medical history, main clinical manifestations and pertinent evaluations previously performed (ophthalmological evaluation, visual evoked potentials, electroretinogram, electroencephalogram, imaging tests including computerized axial tomography or brain magnetic resonance imaging) at diagnosis, in addition to the result of the most recent neurological examination and current treatment.

All study procedures were carried out in accordance with the Declaration of Helsinki, Good Clinical Practice Standards and local Costa Rican regulations.


Nine patients with a previous clinical diagnosis of NCL were identified. The average age of the subjects when the DNA sample was obtained was 9.9 ± 2.7 years (mean ± SD). The initial symptoms appeared at 3.9 ± 0.6 years on average (range 3-5 years) and the typical age at the time of the clinical diagnosis was approximately 7 years (range 3-10 years). Females outnumbered males in a 2:1 ratio. Most patients (77.8%, n = 7) did not report a significant medical history before the onset of symptoms related to the disease.

The Costa Rican mutation (homozygous nonsense variant in exon 3 c.214G> T in the CNL6 gene) was reported in approximately 90% (n = 8) of study participants. In all cases where the Costa Rican CLN6 mutation was present, it was accompanied by a substitution in intron 2 (c.198 + 104T>C, Table 1) as previously described [4, 22].

Table 1 Patient´s main sociodemographic characteristics, medical history and genetic mutation

Most of the patients were born in and currently live in areas distant from San José, Costa Rica´s capital city. There was a fraternal relationship identified between two patients who live in the province of Limón. Nevertheless, there was no evidence suggesting the presence of specific geographic areas with a higher frequency of cases (Fig. 1). Likewise, no consanguineous relationships were reported between the parents of study participants.

Fig. 1
figure 1

Geographic distribution of cases. Blue pin indicates the patient without the CLN6 Costa Rican mutation

Gait disorders, vision loss and speech disturbances were the most frequent initial manifestations registered in medical records. Patient´s specific neurological signs and symptoms can be observed in Tables 2 and 3. At the time of clinical diagnosis, 77.7% (n = 7) of the cases presented abnormalities in the ophthalmological assessment with 87.5% (n = 7) of study subjects presenting with altered visual potentials when such data were collected. The majority of study participants showed abnormalities in the EEG and neuroimaging tests, in which cortical, subcortical, and cerebellar atrophies were common (Table 2).

Table 2 Clinical manifestations and evaluations at diagnosis
Table 3 Most recent neurological examination findings and current treatment

The review of subject´s medical records allowed for a qualitative comparison between the initial clinical manifestations and the findings from the most recent neurological examination, showing a substantial deterioration in physical and functional capabilities over the observation period (Table 3). Valproic acid, carbamazepine and clonazepam were the medications mostly prescribed for the treatment of seizures.

In study patient A, genetic sequencing did not identify the Costa Rican mutation to confirm variant late infantile NCL. Full mutation analysis including: CLN1/PPT1, CLN2/TPP1, CLN3, CLN5, CLN6, CLN7, CLN8 and CLN10/CTSD was suggested for this patient. However, currently our Institution does not have the possibility to extend further genetic testing. After receiving the negative results for this patient new tests were performed and no data supporting alterations in metabolic or biochemical parameters was identified. Genetic confirmation of progressive leukoencephalopathy was also recommended. Currently the patient is receiving palliative care.


Worldwide, it has been reported that the initial clinical manifestations in CLN6 disease occur between 2 and 4 years of age [13], however in this investigation, the cases analyzed trended towards the older end of this range with regards to symptom onset (3.9 ± 0.6), with a range between 3 and 5 years of age. This may be due to the small number of cases studied, or possibly to certain variations in the clinical course of the disease linked to this causative mutation as has previously been reported for Costa Rican patients [20]. The age of diagnosis in this study was an average of seven years. This could be due in part to the challenges associated with diagnosis of a complex rare disease in a locality with limited utilization of genetic testing. In this patient cohort, females outnumbered males 2:1. This level of sex disparity has not been reported in clinical literature and is likely due to the small sample size. Differences in severity between the sexes have been documented for some forms of NCL, with more aggressive forms commonly reported in female patients, however this was not recapitulated in our study [29, 30].

The genetic alterations identified in the study population, pointedly the Costa Rican mutation and the substitution polymorphism in intron 2, have been previously reported [4, 22]. This substitution polymorphism has also been described in Argentinian populations [4, 28]. In the Costa Rican Batten disease population, the homozygous mutation and the presence of the polymorphism suggests that the polymorphism and the damaging mutation are inherited as a haplotype. Thus, unlike many other NCL mutations, the Costa Rican c.214G> T mutation has been associated with the founder effect [20, 31]. It is important to mention, that despite not having carried out multi-generation genealogical studies, the presence of the specific haplotype in all study samples, the absence of consanguinity registered in medical records and the varied geographical locations where study subjects were born and live, supports this local founder effect for this allele. It has been suggested that this founder effect was introduced in the initial pool of genes from the time of the Spanish and Portuguese colonization. This hypothesis has been mentioned in other medical conditions described in our country such as Wilson´s Disease [32, 33].

The main signs and symptoms observed in study participants generally agree with what has been reported worldwide for CLN6 patients, where visual loss, the presence of rapid and involuntary muscle movements, seizures, ataxia, and mental and motor deterioration are the most frequent findings described [16, 17]. Specifically, the published literature establishes that motor regression constitutes one of the first clinical manifestations [15], an aspect confirmed in our study subjects, where gait disturbances and alterations of motor skills were near constant findings in the initial stages of the disease (Table 2).

Where neuroimaging studies were available, cortical and / or subcortical atrophy were common findings, as has been consistently reported in NCLs [15, 17,18,19]. Regarding imaging modalities, magnetic resonance imaging (MRI) had limited availability in Costa Rica over the study period; many patient records thus only had computed tomography (CT) scans. Likewise, ERG equipment was not operational for the duration of the study period and ERG data is available for only three patients in the study. In the majority of the analyzed cases, deterioration was reported in both the ophthalmological evaluation and in the visual evoked potentials (defective macular light reflection, optic disc pallor, attenuation of retinal vessels, pigmentary retinal changes, macular degeneration and optic atrophy); all of these findings are congruent with what has been described previously in medical literature [34]. These changes can occur even before the onset of vision loss, which was documented in the present investigation. In this study, similar to what has been reported worldwide, substantial disease progression was observed when comparing the initial clinical manifestations reported in medical records with the findings of the most recent neurological examination [35, 36].

Current therapeutic options in this disease include symptom management for: seizures, sleep problems, extrapyramidal symptoms, behavior problems, anxiety and psychosis. Seizures in NCLs are often refractory to treatment and require the prescription of multiple antiseizure medications such as sodium valproate, lamotrigine, topiramate, levetiracetam, carbamazepine, and benzodiazepine derivatives [37, 38]. There were no major differences regarding the main antiseizure medications prescribed when compared to other countries, and possible variations would be due mainly to the availability of the medication in the country and in the social security health care system (CCSS).

Regarding the study participant in whom the c.214G>T Costa Rican mutation was not identified, it is possible that mutations in other NCL genes could be responsible for  the symptoms, as has been documented in other Costa Rican patients [20, 22]. It is worth noting that this was the only patient that presented with a normal ophthalmic evaluation and normal visual evoked potential at diagnosis, demonstrative of some disparity in their disease presentation. Additionally, while vast majority of Costa Rican patients with NCL are treated in the HNN, the possibility (although low) of patients in other regional or private healthcare centers cannot be disregarded.


Collectively, this investigation confirms the presence of the c.214G>T Costa Rican mutation in most Costa Rican patients with clinical symptoms of NCL and sustains that the clinical characteristics of these patients are similar to those described in other regions globally.

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to internal policies of the CCSS that prohibited the publication of any patient’s information in any website outside of its network, but are available from the corresponding author on reasonable request.



Neuronal Ceroid Lipofuscinosis Type 6


Costa Rica´s Social Security System


Neuronal ceroid lipofuscinoses


Costa Rica’s National Children’s Hospital


Deoxyribonucleic acid


Endoplasmic reticulum


Next generation sequencing


South Dakota


United States of America






NO data


Optic nerve


Computerized tomography


Visually evoked potentials


Costa Rica’s Association for Children with Progressive Neurological Diseases


  1. Warrier V, Vieira M, Mole SE. Genetic basis and phenotypic correlations of the neuronal ceroid lipofusinoses. Biochim Biophys Acta Mol Basis Dis. 2013;1832(11):1827–30.

    Article  CAS  Google Scholar 

  2. Nelvagal H, Lange J, Takahashi K, Tarczyluk-Wells M, Cooper J. Pathomechanisms in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta Mol Basis Dis. 2019;30:165570.

    Google Scholar 

  3. Johnson T, Cain J, White K, Ramirez-Montealegre D, Pearce D, Weimer J. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15(3):161–78.

    Article  Google Scholar 

  4. Kousi M, Lehesjoki A, Mole S. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat. 2012;33(1):42–63.

    Article  CAS  Google Scholar 

  5. Mole S. Neuronal ceroid lipofuscinoses (NCL). Eur J Paediatr Neurol. 2006;10(5–6):255–7.

    Article  Google Scholar 

  6. Butz E, Chandrachud U, Mole S, Cotman S. Moving towards a new era of genomics in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta Mol Basis Dis. 2019;30:165571.

    Google Scholar 

  7. Bajaj L, Sharma J, di Ronza A, Zhang P, Eblimit A, Pal R, et al. A CLN6-CLN8 complex recruits lysosomal enzymes at the ER for Golgi transfer. J Clin Investig. 2020;130(8):4118–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Cárcel-Trullols J, Kovács AD, Pearce DA. Cell biology of the NCL proteins: what they do and don’t do. Biochim Biophys Acta Mol Basis Dis. 2015;1852(10):2242–55.

    Article  Google Scholar 

  9. von Eisenhart-Rothe P, Grubman A, Greferath U, Fothergill L, Jobling A, Phipps J, et al. Failure of autophagy-lysosomal pathways in rod photoreceptors causes the early retinal degeneration phenotype observed in Cln6nclf mice. Investig Ophthalmol Vis Sci. 2018;59(12):5082–97.

    Article  Google Scholar 

  10. Heine C, Koch B, Storch S, Kohlschütter A, Palmer D, Braulke T. Defective endoplasmic reticulum-resident membrane protein CLN6 affects lysosomal degradation of endocytosed arylsulfatase A. J Biol Chem. 2004;279(21):22347–52.

    Article  CAS  Google Scholar 

  11. Cain J, Likhite S, White K, Timm D, Davis S, Johnson T, et al. Gene therapy corrects brain and behavioral pathologies in CLN6-Batten disease. Mol Ther. 2019;27(10):1836–47.

    Article  CAS  Google Scholar 

  12. Morgan J, Magee H, Wong A, Nelson T, Koch B, Cooper J, et al. A murine model of variant late infantile ceroid lipofuscinosis recapitulates behavioral and pathological phenotypes of human disease. PLoS ONE. 2013;8(11):e78694.

    Article  CAS  Google Scholar 

  13. Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta Mol Basis Dis. 2015;1852(10):2237–41.

    Article  CAS  Google Scholar 

  14. Nita DA, Mole SE, Minassian BA. Neuronal ceroid lipofuscinoses. Epileptic Disord. 2016;18(S2):73–88.

    Article  Google Scholar 

  15. Cannelli N, Garavaglia B, Simonati A, Aiello C, Barzaghi C, Pezzini F, et al. Variant late infantile ceroid lipofuscinoses associated with novel mutations in CLN6. Biochem Biophys Res Commun. 2009;379(4):892–7.

    Article  CAS  Google Scholar 

  16. Nafi O, Ramadan B, Riess O, Buchert R, Froukh T. Two cases of variant late infantile ceroid lipofuscinosis in Jordan. World J Clin cases. 2019;7(2):203–8.

    Article  Google Scholar 

  17. Peña J, Montiel-Nava C, Delgado W, Hernández M, Cardozo J, Mora E, et al. Characterization of neuronal ceroid lipofuscinosis in Venezuelan children. Rev Neurol. 2004;38(1):42–8.

    PubMed  Google Scholar 

  18. Petersen B, Handwerker M, Huppertz H. Neuroradiological findings in classical late infantile neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1996;15(4):344–7.

    Article  CAS  Google Scholar 

  19. Kohan R, Pesaola F, Guelbert N, Pons P, Oller-Ramírez A, Rautenberg G, et al. The neuronal ceroid lipofuscinoses program: A translational research experience in Argentina. Biochim Biophys Acta. 2015;1852(10 Pt B):2301–11.

  20. Sharp J, Wheeler R, Parker K, Gardiner R, Williams R, Mole S. Spectrum of CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis. Hum Mutat. 2003;22(1):35–42.

    Article  CAS  Google Scholar 

  21. Markham A. Cerliponase Alfa: first global approval. Drugs. 2017;77(11):1247–9.

    Article  CAS  Google Scholar 

  22. Wheeler R, Sharp J, Schultz R, Joslin J, Williams R, Mole S. The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. Am J Hum Genet. 2002;70(2):537–42.

    Article  CAS  Google Scholar 

  23. Matsumoto A, Nagashima M, Iwama K, Mizuguchi T, Makino S, Ikeda T, et al. Rapid progression of a walking disability in a 5-year-old boy with a CLN6 mutation. Brain Dev. 2019;41(8):726–30.

    Article  Google Scholar 

  24. Gao H, Boustany R-MN, Espinola JA, Cotman SL, Srinidhi L, Antonellis KA, et al. Mutations in a Novel CLN6-Encoded Transmembrane Protein Cause Variant Neuronal Ceroid Lipofuscinosis in Man and Mouse. Am J Hum Genet. 2002;70(2):324–35.

  25. Auger KJ, Ajene A, Lerner T. Progress toward the Cloning of CLN6, the gene underlying a variant LINCL. Mol Genet Metab. 1999;66(4):332–6.

    Article  CAS  Google Scholar 

  26. Haines JL, Boustany RM, Alroy J, Auger KJ, Shook KS, Terwedow H, et al. Chromosomal localization of two genes underlying late-infantile neuronal ceroid lipofuscinosis. Neurogenetics. 1998;1(3):217–22.

    Article  CAS  Google Scholar 

  27. Boustany R-M. Neurodystrophies and lipodosis. In: Moser H, editor. Handbook of clinical neurology, vol. 22. Amsterdam: Elsevier; 1997. p. 671–700.

    Google Scholar 

  28. Mole S. UCL NCL Mutation and, Patient Database [Internet]. 2019 [cited 2019 Nov 15]. Available from:

  29. Cialone J, Adams H, Augustine E, Marshall F, Kwon J, Newhouse N, et al. Females experience a more severe disease course in Batten disease. J Inherit Metab Dis. 2012;35(3):549–55.

    Article  Google Scholar 

  30. Ostergaard J. Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights. Degener Neurol Neuromuscul Dis. 2016;6:73–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Carvajal-Carmona L, Ophoff R, Service S, Hartiala J, Molina J, Leon P, et al. Genetic demography of Antioquia (Colombia) and the Central Valley of Costa Rica. Hum Genet. 2003;112(5–6):534–41.

  32. Herra SA, Hevia FJ, Vargas M, Schosinsky K. Fulminant Wilson’s disease in Costa Rica. Clinico-pathological study of 7 cases. G E N. 1990;44(1):9–14.

  33. Loudianos G, Dessi V, Lovicu M, Angius A, Figus A, Lilliu F, et al. Molecular characterization of Wilson disease in the Sardinian population—evidence of a founder effect. Hum Mutat. 1999;14(4):294–303.

    Article  CAS  Google Scholar 

  34. Verma R, Raut T, Tiwari N, Malhotra K, Hussain N, Malhotra H. Late infantile neuronal ceroid lipofuscinosis: a case report with review of literature. Ann Indian Acad Neurol. 2013;16(2):282–5.

    Article  Google Scholar 

  35. Simonati A, Williams R, Nardocci N, Laine M, Battini R, Schulz A, et al. Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5. Dev Med Child Neurol. 2017;59(8):815–21.

    Article  Google Scholar 

  36. Steinfeld R, Heim P, von Gregory H, Meyer K, Ullrich K, Goebel HH, et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients withCLN2 mutations. Am J Med Genet. 2002;112(4):347–54.

    Article  Google Scholar 

  37. Mole S, Haltia M. The Neuronal Ceroid-Lipofuscinoses (Batten Disease). In: Roger N, Rosenberg R, JM P, editors. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease. San Diego, California; 2015. p. 793–808.

  38. Al-Muhaizea M, Al-Hassnan Z, Chedrawi A. Variant late infantile neuronal ceroid lipofuscinosis (CLN6 gene) in Saudi Arabia. Pediatr Neurol. 2009;41(1):74–6.

    Article  Google Scholar 

Download references


To Mrs. Yamileth Chaves-Soto, president of Costa Rica´s Association for Children with Progressive Neurological Diseases (APRONEP), for her vision and determination in ensuring that this study could be carried out and who also collaborated with the logistical aspects for study participants and their relatives. To Mr. Pablo Solís-Quesada for his collaboration in this study and Sebastián Rojas-Chaves MD for his participation in graphic design.


This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations



ASC, RBP and AEM contributed to the design and implementation of the research, to the analysis of the results and to the writing of the manuscript. AUC, AGM, LHC and SBL were the head doctors of the patients in the study, they contribute with the data collection and review the written manuscript. JW did the genetic sequencing of the patients and helped with the writing of this article. ABM contributed with the extensive bibliographic search and supported the writing of the manuscript. JB participated in the review, writing and as a consultant for clinical insight of the disease. ASR was part of the data collection team and writing, contributed to the data analysis and the design of the figures and graphics. All authors read and approved the final manuscript.

Corresponding author

Correspondence to A. Echeverri-McCandless.

Ethics declarations

Ethics approval and consent to participate

After obtaining approval from the Institution’s Scientific Ethics Committee (CEC-CENTRAL-CCSS) and authorization from the Director of Costa Rica´s National Children´s Hospital (HNN), the parents of all patients with a clinical diagnosis of Batten disease currently treated at the HNN Neurology Department were contacted, the study was explained, and the investigators invited the parents so their child could participate. All parents agreed and signed an informed consent form so the patient could participate.

Consent for publication:

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Badilla-Porras, R., Echeverri-McCandless, A., Weimer, J.M. et al. Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience. Orphanet J Rare Dis 17, 13 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: